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Plasma homocysteine concentration predicts mortality in non-insulin- shown that mortality is related to several factors that
dependent diabetic patients with and without albuminuria. are potentially modifiable or preventable, such as pre-
Background. A high plasma total homocysteine (tHcy) concentra-
existing coronary heart disease (CHD), presence of mi-tion is a risk factor for cardiovascular disease in the nondiabetic popula-
tion and in nondiabetic patients with end-stage renal disease. croalbuminuria and macroalbuminuria, glycemic con-
Methods. We prospectively evaluated the impact of tHcy concentrations trol, and systolic blood pressure (BP) [1].
on mortality in 211 white non-insulin-dependent diabetic (NIDDM)
A high plasma or serum level of total homocysteinepatients of less than 70 years of age at entry (61 with microalbuminuria
and 44 with macroalbuminuria). They were followed for a median of (tHcy) is a risk factor for atherothrombotic disease [2, 3]
6.4 (range 0.2 to 7.1) years. that has recently come under increased scrutiny [4–8].
Results. At the end of the follow-up period, 49 of 211 (23%) patients
High tHcy concentrations can be lowered with folic acidhad died, 30 (61%) from cardiovascular disease. Univariate Cox sur-
vival analysis revealed that baseline tHcy level (1 mmol/liter) was supplementation [9]. A recent population-based study
associated with an increased all-cause mortality risk of 1.11 [95% con- showed that the association between hyperhomocys-
fidence interval (CI) 1.08 to 1.15, P , 0.0001], and a cardiovascular
teinemia and atherosclerotic vascular disease was espe-mortality risk of 1.09 (CI 1.03 to 1.16, P , 0.01). The six-year cumulative
all-cause mortality hazard was 44%, 14%, and 15% in the high (tHcy $ cially strong in patients with NIDDM as compared with
8.2 mmol/liter), the middle (tHcy 6.2–8.1 mmol/liter), and the low (tHcy # nondiabetic subjects [10]. In addition, hyperhomocys-
6.1 mmol/liter) tertile of tHcy levels, respectively (P , 0.001 high vs.
teinemia is extremely common among patients with mod-middle; P , 0.001 high vs. low; and P 5 0.88 middle vs. low). Cox
proportional hazards regression analysis revealed significant predictors erate to severe renal failure (glomerular filtration rate
of all-cause mortality to be tHcy level (per 1 mmol/liter), relative risk of less than 50 to 60 ml/min) [9, 11], and there is recent
1.09 (1.03 to 1.14); pre-existing coronary heart disease (yes vs. no),
evidence that hyperhomocysteinemia confers an increasedrelative risk 1.98 (1.09 to 3.61); log10 albumin excretion rate (AER;
factor 10), relative risk 1.89 (1.31 to 2.74); and age (per 1 year), relative risk of incident cardiovascular disease in patients with
risk 1.08 (1.03 to 1.13). Predictors of cardiovascular mortality were end-stage renal failure [12, 13] or severely impaired renal
pre-existing coronary heart disease, log10 AER, and age. tHcy level function [14]. There are no prospective data, however,did not predict cardiovascular mortality independently of these risk
factors. on the impact of hyperhomocysteinemia on mortality
Conclusion. Plasma tHcy concentration is a significant predictor of that specifically focused on NIDDM patients with and
mortality in NIDDM patients with or without albuminuria.
without renal disease.
In view of these considerations, we examined the rela-
tionship between plasma tHcy concentration and all-causeNon–insulin-dependent diabetes mellitus (NIDDM) is
and cardiovascular mortality in a cohort of 211 patientswell known to be associated with an increased risk of all-
with NIDDM, 105 of whom had microalbuminuria orcause and cardiovascular mortality. We have previously
macroalbuminuria.
Key words: cardiovascular disease, NIDDM, microalbuminuria, mac-
METHODSroalbumnuria.
The study population was based on all (N 5 267) whiteReceived for publication June 18, 1998
NIDDM patients of less than 70 years of age attendingand in revised form August 19, 1998
Accepted for publication August 19, 1998 the Hvido¨re Hospital during the period of November
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Table 1. Clinical data at baseline in 211 non-insulin-dependent assessed by fundus photography after pupillary dilata-
diabetic patients
tion. Body mass index (BMI in kg/m2) was calculated.
Sex M/F 127/84 Present medication and smoking history were recorded.
Age years 58 (23–69)
Current smokers were defined as subjects smoking oneKnown duration of diabetes years 10 (4–34)
Treatment (diet/oral hypoglycemic agent/insulin) % 22/41/37 or more cigarette, cigar, or pipe per day.
Mean (sd) hemoglobin A1c % 8.8 (1.8) The cohort was followed prospectively until January
Mean (sd) BMI kg/m2 28.5 (4.9)
1, 1997, or until death. All patients were traced throughRetinopathy (nil/background/proliferative) % 43/47/10
Normoalbuminuria/microalbuminuria/ 106/61/44 the national register at the beginning of 1997. If a subject
macroalbuminuria N had died before January 1, 1997, the date of death wasAER mg/24 hr 29 (1–4770)
recorded, and information on the cause of death wasSerum creatinine lmol/liter 76 (43–539)
1CCr ml/min 102 (23–248) obtained from death certificates. All death certificates
Mean (sd) systolic BP mm Hg 150 (24)
were reviewed independently by at least two observers,Mean (sd) diastolic BP mm Hg 84 (11)
Hypertension N 113 and the primary cause of death was recorded. Additional
Mean (sd) serum cholesterol mmol/liter 5.8 (1.4) information from postmortem reports was not included.
Mean (sd) serum HDL cholesterol mmol/liter 1.18 (0.40)
Death from cardiovascular disease (ICD codes 410–438)Pre-existing 2CHD N 49
Current smokers N 101 included death from myocardial infarction, cardiac insuf-
Plasma homocysteine lmol/liter 7.0 (2.4–46.7) ficiency, or stroke. Death certificates were unobtainable
Values are medians (ranges) unless stated otherwise. Abbreviations are: BMI, for one patient who died abroad. The observation periodbody mass index; AER, albumin excretion rate; 1CCr, estimated creatinine clear-
ance; BP, blood pressure; HDL, high-density lipoprotein; and 2CHD, coronary was defined as the number of days from the date of
heart disease defined on the basis of electrocardiographic Minnesota scores. examination in 1989 to 1990 to the date of death or
January 1, 1997.
Approval for the study was obtained from the Ethical
Committee of the Copenhagen County.study, 56 patients were excluded due to lack of material
for tHcy concentration determinations. These patients
Laboratory proceduresdid not differ significantly from those included with re-
Peripheral venous blood was collected in the nonfast-gard to demographic and clinical variables (data not
shown). The remaining 211 patients form the cohort of ing state into tubes containing sodium citrate (1:9 vol/
this study. Baseline characteristics of the cohort are vol) kept at room temperature and centrifuged within
shown in Table 1. 60 minutes, which is sufficient to prevent increases in
Non-insulin dependence was defined as follows: treat- plasma tHcy resulting from ex vivo generation of homo-
ment by diet alone or diet combined with oral hypoglyce- cysteine by erythrocytes [18]. The plasma fraction was
mic agents; insulin treatment and diabetes onset after then transferred to plastic vials stored at –808C and as-
the age of 40 years and a body mass index (BMI) above sayed in 1996. Total (free plus protein bound) homocys-
normal (25 kg/m2 or more in women and 27 kg/m2 or more teine levels are stable in serum or plasma stored for 10
in men) at the time of diagnosis; or insulin treatment, years or more [19, 20]. Plasma tHcy was measured in
normal weight, and a glucagon-stimulated C-peptide duplicate as previously described in detail [21]. The intra-
value of 0.60 pmol/ml or more [15]. A glucagon test was assay and interassay coefficients of variation were 2.1%
performed whenever the BMI was less than 25 kg/m2 in and 5.1%. The hemoglobin A1c level (normal range 4.1women and less than 27 kg/m2 in men at the time of
to 6.1%) [22] and serum concentrations of creatinine
diagnosis [16].
[23], total cholesterol [24], and high-density lipoproteinArterial BP was measured twice using the right arm
(HDL) cholesterol [24] were determined.after at least 10 minutes of rest while the patient was
Urine collection was carried out during unrestrictedin the supine position using an automatic oscillometric
daily life activity. If bacterial growth was found, urinemanometer (Takeda Medical UA-751; Takeda, Tokyo,
collection was repeated after treatment. The urinary al-Japan) recording phase I (systolic) and phase V (dia-
bumin concentration was determined by radioimmuno-stolic). Arterial hypertension was defined according to
assay [25], and the albumin excretion rate (AER) wasthe World Health Organization criteria: systolic BP of
calculated. Persistent normoalbuminuria was defined as160 mm Hg or more and/or diastolic BP of 95 mm Hg
AER of less than 30 mg/24 hr, persistent microalbuminu-or more and/or if antihypertensive treatment was being
ria as AER of 30 to 299 mg/24 hr, and persistent macroal-prescribed. A 12-lead resting electrocardiogram was
buminuria as AER of 300 mg/24 hr or more in twocoded using the Minnesota codes [17], and CHD was
out of three consecutive 24-hr collections. Estimation ofdefined as probable myocardial infarction (Minnesota
creatinine clearance (CCr) was done according to thecode 1.1–1.2) or possible myocardial ischemia (Minne-
sota code 1.3, 4.1–4.4, 5.1–5.3, or 7.1). Retinopathy was formula described by Cockcroft and Gault [26].
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Table 2. Plasma homocysteine concentrations according to the level of renal function
Normal Mildly impaired Moderately to severely
renal function renal function impaired renal function
(N 5 163) (N 5 34) (N 5 6)
CCr ml/min $76 51–75 #50
Plasma homocysteine lmol/liter 6.9 (2.4–16.5) 7.7 (3.9–15.1) 13.6 (7.0–46.7)
P value ,0.05a ,0.005a, ,0.05b
Values are medians (ranges). Eight subjects with missing creatinine values were excluded. CCr is the estimated creatinine clearance.
a Versus normal renal function
b Versus mildly impaired renal function
Statistical methods Plasma tHcy level was significantly associated with
male gender (P , 0.01), serum creatinine (P , 0.001),Values are given as mean and sd and median and
CCr (inversely; P , 0.001; Table 2), log10 AER (P ,range. Linear regression analyses were used to examine
0.001), systolic BP (P , 0.01), diastolic BP (P , 0.01),the relation between tHcy level and other variables. The
pre-existing CHD (median, 7.8 mmol/liter in subjectsKruskal–Wallis test was used to compare tHcy levels
with vs. 6.9 mmol/liter in those without CHD; P , 0.01),when patients were grouped according to level of renal
and serum HDL cholesterol (inversely; P , 0.05). Theimpairment. All tests were two sided.
plasma tHcy level was not significantly related to age,The survival data were analyzed using statistical meth-
smoking, serum cholesterol, hemoglobin A1c, BMI, orods for censored failure times [27, 28]. The cumulative
duration of diabetes.all-cause and cardiovascular mortality hazards were eval-
uated for tertiles of tHcy by the Nelson-Aalen estimate
Effect of tHcy and other selected baseline variables
and were compared using the log-rank test [27]. Cox
on all-cause and cardiovascular mortality
proportional hazards multiple regression analyses [27,
The median follow-up period was 6.4 (range 0.2 to28] were performed to examine the baseline variables
7.1) years. At the end of follow-up, 49 of the 211 (23%)predictive of all-cause and cardiovascular mortality. The
patients had died, 30 (61%) from cardiovascular diseasemodels used included those baseline variables that were
(myocardial infarction, N 5 9; congestive heart failure,a priori considered to be potentially important predictors
N 5 16; and stroke N 5 5), 4 from end-stage renal disease,of all-cause and cardiovascular mortality: sex, age, known
2 from infections, 3 from cancer, 5 from other causes,duration of diabetes, BMI, tHcy, serum creatinine, smok-
and 5 from unknown causes. The all-cause mortality rateing, serum cholesterol and HDL-cholesterol, hemoglo-
per 100 person years was 3.9. Per 100 person years ofbin A1c, systolic and diastolic BP, CCr, pre-existing CHD,
observation, the mortality rate was 1.4 in patients withand AER, and stepwise backward selection was used.
a normal AER, 4.4 in patients with microalbuminuria,Results are described as relative risk (hazard ratio). AER
and 11.5 in patients with macroalbuminuria (normoalbu-was logarithmically transformed (log10) owing to the
minuria vs. microalbuminuria P , 0.01; normoalbumin-skewed distribution. Relative risk thus corresponds to a
uria vs. macroalbuminuria P , 0.001; microalbuminuriatenfold increase in AER. Univariate results were calcu-
vs. macroalbuminuria P , 0.01); 2.5 in patients withoutlated for continuous and class variables. Possible interac-
and 9.2 in patients with pre-existing CHD (P , 0.001);tions between tHcy and sex, and smoking and systolic
3.2, 6.5, and 20.0 in patients with normal (CCr $ 76 ml/or diastolic BP were examined by including products of
min), mildly impaired (CCr 51 to 75 ml/min), and moder-the corresponding original variables as covariates in the
ately to severely impaired (CCr # 50 ml/min) renal func-multiple regression analysis for all-cause mortality. Con-
tion, respectively (normal vs. mildly impaired, P , 0.05;fidence intervals (CI) were based on the normal approxi-
normal vs. moderate to severely impaired, P , 0.001;mation on the logarithmic scale.
mildly vs. moderately to severely impaired, P , 0.05);
and 2.2, 2.4, and 7.7 in patients in the lowest (tHcy #
RESULTS 6.1 mmol/liter), middle (tHcy 6.2 to 8.1 mmol/liter), and
Homocysteine highest (tHcy $ 8.2 mmol/liter) tertile of tHcy (low vs.
middle, P 5 0.88; low vs. high, P , 0.001; middle vs. high,The median tHcy level at baseline was 7.0 (range 2.4
P , 0.001). Figure 1 indicates the relative importanceto 46.7; second highest value, 17.4) mmol/liter (Table 1).
of tertiles of tHcy levels for the cumulative all-causeThe prevalence of hyperhomocysteinemia, based on cut-
mortality hazard. The six-year cumulative all-cause mor-off points equal to or above 12, 15, 16, 17, and 18 mmol/
tality hazard was 44%, 14%, and 15% in the high, theliter, was 7.6% (95% CI 4.4% to 12.0%), 2.8% (1.0%
middle, and the low tertile of tHcy levels, respectivelyto 6.1%), 1.4% (0.3% to 4.1%), 1.0% (0.1% to 3.4%),
and 0.5% (0.0% to 2.6%), respectively. (P , 0.001, high vs. middle; P , 0.001, high vs. low; and
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Fig. 1. Cumulative all-cause mortality hazard according to tertiles of Fig. 2. Cumulative cardiovascular mortality hazard according to ter-
tiles of plasma total homocysteine levels and according to duration ofplasma total homocysteine levels and according to duration of follow-
up in 211 non-insulin-dependent diabetic patients. Lines are: ( ——, N follow-up in 211 non-insulin-dependent diabetic patients. Lines are:
( ——, N 5 72) low, homocysteine # 6.1 mmol/liter; ( – – –, N 5 69)5 72) low, homocysteine # 6.1 mmol/liter; (–––, N 5 69) middle,
homocysteine 6.2 to 8.1 mmol/liter; (–-–-, N 5 70) high, homocysteine middle, homocysteine 6.2 to 8.1 mmol/liter; ( – - – -, N 5 70) high, homo-
cysteine $ 8.2 mmol/liter. P 5 0.91, low vs. middle; P , 0.02, low vs.$ 8.2 mmol/liter. P 5 0.88, low vs. middle; P , 0.001, low vs. high; and
P , 0.001, middle vs. high. high; P , 0.05, middle vs. high.
Table 3. Relative risk of death for non-insulin-dependent diabetic
P 5 0.88, middle vs. low). Figure 2 indicates the relative patients by univariate Cox regression analysis
importance of tertiles of tHcy levels for the cumulative
95%
cardiovascular mortality hazard. The six-year cumulative Relative Confidence
Variable risk interval P valuecardiovascular mortality hazard was 24%, 9%, and 11%
in the high, the middle, and the low tertile of tHcy levels, Sex female 0.84 0.47–1.50 0.55
Age 1 year 1.08 1.04–1.13 , 0.001respectively (P , 0.05, high vs. middle; P , 0.02 high
Known duration of diabetes 1 year 1.03 0.99–1.07 0.10vs. low; and P 5 0.91, middle vs. low). Treatment
Diet alone 1.00 — —
Cox survival analyses Oral hypoglycemic agent(s) 4.22 1.25–14.17 , 0.001
Insulin 6.40 1.93–21.25 , 0.001
In univariate Cox regression analysis, age, treatment Hemoglobin A1c 1% 1.19 1.02–1.38 , 0.05
Body mass index 1 kg/m2 1.03 0.97–1.08 0.38with oral hypoglycemic agents or insulin, hemoglobin
Retinopathy (any) 1.93 1.03–3.61 , 0.05A1c level, presence of retinopathy, presence of microal- Albuminuria
buminuria or macroalbuminuria, log10 AER, serum cre- Normoalbuminuria 1.00 — —
Microalbuminuria 3.25 1.44–7.36 , 0.001atinine level, CCr, systolic BP, pre-existing CHD, and
Macroalbuminuria 8.92 4.14–19.23 , 0.001plasma tHcy level were associated with a risk of death
Log10 AER (factor 10) 2.57 1.85–3.55 , 0.001
(Table 3). Plasma tHcy was a significant predictor of all- Serum creatinine 1 lmol/liter 1.009 1.006–1.012 , 0.001
CCr 1 ml/min 0.975 0.964–0.985 , 0.001cause and cardiovascular mortality in univariate and in
Systolic BP 1 mm Hg 1.016 1.004–1.027 , 0.01age-adjusted Cox regression analyses (Table 4). Diastolic BP 1 mm Hg 1.005 0.979–1.032 0.72
Backward stepwise Cox multiple regression analysis Serum cholesterol 1 mmol /liter 1.08 0.89–1.31 0.42
Serum HDL cholesterol 1 mmol /liter 0.65 0.30–1.43 0.28indicated that tHcy level, log10 AER, age, and pre-existing
Pre-existing coronary heart disease 3.80 2.15–6.70 , 0.001CHD were significantly and independently associated Current smokers 0.97 0.55–1.70 0.92
with all-cause mortality (Table 5). Possible predictors of Plasma homocystein 1 lmol /liter 1.11 1.08–1.15 , 0.001
cardiovascular mortality were also examined in stepwise Abbreviations are: AER, albumin excretion rate; CCr, estimated creatinine
clearance; BP, blood pressure; and HDL, high-density lipoprotein.Cox multiple regression analysis. Pre-existing CHD, log10
AER, and age were significantly associated with cardio-
vascular mortality (Table 6). Plasma tHcy level did not
appear as a significant predictor of cardiovascular mor- isting CHD, CCr and serum creatinine may lead to over-
tality independent of other predictors (Tables 4 and 6). adjustment if pre-existent CHD is an intermediary link-
When tHcy was forced into the model, the relative risk ing tHcy to cardiovascular death, or if CCr and serum
(per 1 mmol/liter) was 1.00 (0.88 to 1.13). Adjusting the creatinine are closely linked to tHcy. We therefore re-
peated the Cox multiple regression analysis withouteffect of tHcy on cardiovascular mortality for pre-ex-
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Table 4. Plasma total homocysteine concentration and mortality in non-insulin-dependent diabetic patientsa
Univariate Age-adjusted Multivariate adjustedb
All-cause mortality 1.11 (1.08–1.15), P , 0.0001 1.13 (1.09–1.18), P , 0.0001 1.09 (1.03–1.14), P , 0.001
Cardiovascular mortality 1.09 (1.03–1.16), P , 0.01 1.10 (1.02–1.19), P , 0.01 1.00 (0.88–1.13), P 5 0.97
a Data are expressed as relative risks and 95% confidence intervals per 1 mmol/liter plasma homocysteine derived from Cox-regression analysis
b Adjusted for age, sex, body mass index, duration of diabetes, serum creatinine, CCr, log10 albumin excretion rate, serum cholesterol, serum HDL cholesterol,
hemoglobin A1c, systolic and diastolic BP, pre-existing coronary heart disease, and smoking.
Table 6. Predictors of cardiovascular mortality in non-insulin-Table 5. Predictors of all-cause mortality in non-insulin-dependent




Relative ConfidenceVariable risk interval P value
Variable risk interval P value
Pre-existing coronary heart
disease (0 5 no; 1 5 yes) 1.98 1.09–3.61 , 0.05 Pre-existing coronary heart
disease (0 5 no; 1 5 yes) 3.89 1.78–8.53 , 0.001Log10 albumin excretion rate
(factor 10)a 1.89 1.31–2.74 , 0.001 Log10 albumin excretion rate
(factor 10)a 2.28 1.43–3.62 , 0.001Plasma homocysteine
1 lmol/liter 1.09 1.03–1.14 , 0.001 Age 1 year 1.08 1.02–1.15 , 0.02
Age 1 year 1.08 1.03–1.13 , 0.001 a Relative risk corresponds to 10-fold increase in albumin excretion rate; one
subject with missing values was excludeda Relative risk corresponds to 10-fold increase in albumin excretion rate; one
subject with missing values was excluded
these covariates. For tHcy, the results were similar to and the six-year cumulative mortality was 23%. Our
those with the initial model (relative risk per 1 mmol/ population is thus representative of high-risk NIDDM
liter, 1.03; range 0.93 to 1.14). Changing the definition patients. Importantly, the association of tHcy with all-
of cardiovascular mortality to include patients who died cause mortality was independent of the presence of mi-
of unclear causes (N 5 5) also gave similar results (data croalbuminuria or macroalbuminuria and pre-existent
not shown). In these analyses, the main variables respon- CHD, and also of other risk factors, such as age, de-
sible for removing the effect of tHcy were log10 AER creased CCr, and hemoglobin A1c concentration. Prospec-
and (but less so) pre-existing CHD. tive data on tHcy in patients with diabetes or renal dis-
There was no evidence of interaction of tHcy with sex, ease are limited. Three recent studies showed that
smoking, or systolic or diastolic BP for either all-cause hyperhomocysteinemia predicted an adverse cardiovas-
or cardiovascular mortality (data not shown). cular prognosis in (mainly nondiabetic) patients with
end-stage renal disease [12, 13] or with severely impaired
renal function [14]. One population-based study with aDISCUSSION
five-year follow-up indicated that hyperhomocysteine-This prospective study, based on a cohort of 211
mia may be an especially strong risk factor for all-causeNIDDM patients recruited during 1989 to 1990, shows
mortality in NIDDM patients (relative risk for serumthat the plasma tHcy concentration is a significant pre-
tHcy more than 14 mmol/liter was 2.51) as compareddictor of six-year all-cause mortality risk, both in patients
with nondiabetic subjects (relative risk, 1.34) [32]. Takenwith normoalbuminuria and in those with microalbumin-
together, these data suggest that hyperhomocysteinemiauria or macroalbuminuria. For a 5 mmol/liter tHcy increase
is an important risk factor in NIDDM patients with and(approximately 1 sd in most populations) [4], the mortal-
without albuminuria.ity risk increased by 54%. Plasma tHcy was thus a strong
Hyperhomocysteinemia is thought to increase the riskpredictor of an adverse prognosis in this population.
of atherothrombotic disease directly by impairing endo-Many [5, 6, 8, 29], but not all [19, 30, 31], of the
thelial function, stimulating vascular smooth muscle cellprevious prospective studies in nondiabetic populations
proliferation, and altering extracellular matrix proper-found high plasma or serum tHcy to increase the risk of
ties, and also possibly indirectly because hyperhomocys-cardiovascular disease or mortality. The predictive value
teinemia may reflect an inefficiency of intracellular meth-of hyperhomocysteinemia may thus differ among popula-
ylation reactions, which may predispose the patient totions and needs to be examined in specific patient groups.
vascular disease [33–35]. Indeed, hyperhomocysteine-We studied middle-aged white NIDDM patients and
mia, possibly through similar mechanisms, may contrib-found that 50% had microalbuminuria or macroalbumin-
uria, 19% had decreased CCr, 23% had pre-existing CHD, ute to the development of microalbuminuria in diabetic
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and nondiabetic subjects [36]. In the general population, with impaired renal function, respectively, treatment
with vitamin B12 [41] and with vitamin B6 [42] may alsoinadequate plasma concentrations of folate, vitamin B12
and vitamin B6, and the C677T polymorphism of the be useful. The impact of such treatments on the generally
poor prognosis of NIDDM patients, especially those withmethylenetetrahydrofolate reductase gene are important
contributors to increased tHcy concentrations [34]. The albuminuria [1], requires urgent assessment.
NIDDM state per se does not appear to affect tHcy
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The median plasma tHcy concentration in this study
APPENDIXpopulation (7.0 mmol/liter) was relatively low. By com-
parison, in a Dutch population-based study, the median Abbreviations used in this article are: AER, albumin excretion rate;
BMI, body mass index; BP, blood pressure; CCr, creatinine clearance;serum tHcy in NIDDM patients was 11.2 mmol/liter [10].
CHD, coronary heart disease; CI, confidence interval; HDL, high-
The cause of such differences is unclear, but tHcy con- density lipoprotein; NIDDM, non–insulin-dependent diabetes mellitus.
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